|Maine Medicine Weekly Update
October 31, 2021
One Step Closer to COVID Vaccines for Kids; FDA Authorizes Vaccine for Children Ages 5-11
The Food and Drug Administration on Friday, October 29th authorized the Pfizer COVID-19 vaccine for children ages 5-11, one of the final steps in making vaccines available to children under 12.
The Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age is administered as a two-dose primary series, 3 weeks apart, but is a lower dose (10 micrograms) than that used for individuals 12 years of age and older (30 micrograms).
The US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is scheduled to meet this week (Nov. 2 & 3) to discuss further clinical recommendations and how the vaccine should be used. If the panel gives favorable recommendations and CDC Director Rochelle Walensky accepts them, vaccinations can begin pending state guidance.
The Maine CDC has released guidance regarding the availability of Pediatric Pfizer. The Maine Immunization Program (MIP) will make the Pfizer COVID-19 vaccine for 5- 11-year-olds available for enrolled MIP Providers to order through ImmPact.
Important Note: Although the vaccine is available to order now, it cannot be administered until it has received final approval by the US CDC.
· The 5-11 year old population in Maine is ~79,000. Supply is not expected to be an issue.
Maine State survey data show that only ~30-35% of parents will want the vaccine for their kids immediately upon approval. The MMA has throughout the pandemic and will continue to advocate for physicians as a trusted source of medical advice and care for patients and families, and that participation in the vaccination process is imperative to keep Mainers healthy and safe.
ACIP Meeting Information and Resources:
Draft Agenda for November 2nd and 3rd
November 2nd—COVID-19 Vaccines (10:00 a.m. start)
November 3rd—Hepatitis Vaccines, Immunization Schedules, Orthopoxviruses Vaccines, Ebola Vaccine
Webcast Link to Watch Meetings
Read the FDA Press Release to learn more.
Pfizer/BioNTech submitted its clinical trial data to the FDA for emergency use authorization. The trials show the vaccine is 91 percent effective in preventing symptomatic disease for children ages 5 to 11 and was well-tolerated, with few side effects.
FDA briefing documents on the Pfizer-BioNTech COVID-19 vaccine, released before the FDA advisory panel meeting, indicated an immune response and that is was safe and effective in young children.
The White House recently unveiled its plans to vaccinate children between the ages of 5 and 11 years old, pending authorization by the Food and Drug Administration in the coming weeks. The distribution plan will rely on pediatricians, community health centers, schools, and pharmacies to put parents and children at ease, rather than the mass vaccination sites used in the initial rollout for adults.Next Article >
[ return to top ]
ensure delivery of Maine Medicine Weekly Update,
please add 'email@example.com' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm
For more information or to contact us directly, please visit www.mainemed.com | ©